title: Drug interaction between tacrolimus and ertapenem in renal transplantation recipients.
abstract: To show drug interactions between tacrolimus and ertapenem, we retrospectively evaluated 13 renal transplant recipients who had been treated with ertapenem for urinary tract infections during prescription of a constant dose. The mean dose of tacrolimus to achieve desired therapeutic concentrations decreased significantly after beginning ertapenem. The decrease from 0.079 mg/kg to 0.043 mg/kg occurred 2 days after initiation of ertapenem (P < .005). These results suggest that ertapenem, which is not metabolized through the cytochrome (CYP) P450 3A metabolic pathway, interacts with tacrolimus by an unknown mechanism. This report recommends tacrolimus concentration monitoring and dose reductions when the two drugs are administered in combination.
authors.affiliation: Department of General Surgery, Dicle University Medical Facility, Diyarbakir, Turkey.
authors.forename: F
authors.initials: F
authors.lastname: Bora
authors.forename: I
authors.initials: I
authors.lastname: Aliosmanoglu
authors.forename: H
authors.initials: H
authors.lastname: Kocak
authors.forename: A
authors.initials: A
authors.lastname: Dinckan
authors.forename: H B
authors.initials: HB
authors.lastname: Uslu
authors.forename: F
authors.initials: F
authors.lastname: Gunseren
authors.forename: G
authors.initials: G
authors.lastname: Suleymanlar
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D054796:Drug Dosage Calculations; D004347:Drug Interactions; D016903:Drug Monitoring; D000077727:Ertapenem; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D055815:Young Adult; D047090:beta-Lactams / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D007166:Immunosuppressive Agents; D047090:beta-Lactams; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D000077727:Ertapenem; D016559:Tacrolimus